The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors
Open Access
- 1 January 2013
- journal article
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 6 (1) , 45
Abstract
VEGF may play a role in the pathogenesis of cancer disease, for example in cell growth, proliferation and angiogenesis. In this study, we investigated plasma levels of this cytokine in comparison to plasma levels of a new biomarker - HE4 and the established tumor marker CA125 in ovarian cancer patients (100) as compared to control groups: patients with a benign ovarian tumor (80) and healthy subjects (50).Keywords
This publication has 61 references indexed in Scilit:
- Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: Correlation with pathological outcomeGynecologic Oncology, 2013
- The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic massGynecologic Oncology, 2013
- Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment responseDiagnostic Pathology, 2013
- Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125Gynecologic Oncology, 2012
- HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseasesTumor Biology, 2011
- Development of a Multimarker Assay for Early Detection of Ovarian CancerJournal of Clinical Oncology, 2010
- TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patientsBMC Cancer, 2010
- Use of a Symptom Index, CA125, and HE4 to predict ovarian cancerGynecologic Oncology, 2010
- The biology of ovarian cancer: new opportunities for translationNature Reviews Cancer, 2009
- Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125Cancer Epidemiology, Biomarkers & Prevention, 2009